Comparison of antidepressant classes and the risk and time course of suicide attempts in adults: Propensity matched, retrospective cohort study

British Journal of Psychiatry

Volumn 208, Issue 3, 2016, Pages 271-279

  Valuck, Robert J ^a   Libby, Anne M ^b   Anderson, Heather D ^a   Allen, Richard R ^c   Strombom, Indiana ^d   Marangell, Lauren B ^e,f   Perahia, David ^g  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c Peak Statistical Services   (United States)

^d GENENTECH INC   (United States)

^e UNIVERSITY OF TEXAS   (United States)

^f Brain Health Consultants   (United States)

^g ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; PAROXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE; ANTIDEPRESSANT AGENT;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DEPRESSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION; PRESCRIPTION; RETROSPECTIVE STUDY; RISK ASSESSMENT; SUICIDE ATTEMPT; CLASSIFICATION; CLINICAL TRIAL; COMORBIDITY; COMPARATIVE STUDY; DEPRESSIVE DISORDER; FACTUAL DATABASE; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL; PSYCHOLOGY; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; UNITED STATES; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; CITALOPRAM; COMORBIDITY; DATABASES, FACTUAL; DEPRESSIVE DISORDER; FEMALE; FLUOXETINE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEROTONIN UPTAKE INHIBITORS; SUICIDE, ATTEMPTED; UNITED STATES; YOUNG ADULT;

EID: 84960331643     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.bp.114.150839     Document Type: Article

References (28)

1. Mayer-Gross W, Slater E, Roth M. Clinical Psychiatry. Bailliere, Tindell and Cassell, 1960.
2. Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 2006; 63: 332-9.
3. Mosholder AD, Pamer CA. Postmarketing surveillance of suicidal adverse events with pediatric use of antidepressants. J Child Adolesc Psychopharmacol 2006; 16: 33-6.
4. Tollefson GD. Fluoxetine and suicidal ideation. Am J Psychiatry 1990; 147: 1691-3.
5. Libby AM, Orton HD, Valuck RJ. Persisting decline in depression treatment after FDA warnings. Arch Gen Psychiatry 2009; 66: 633-9.
6. Libby AM, Brent DA, Morrato EH, Orton HD, Allen R, Valuck RJ. Decline in treatment of pediatric depression after FDA advisory on risk of suicidality with SSRIs. Am J Psychiatry 2007; 164: 884-91.
7. Valuck RJ, Libby AM, Orton HD, Morrato EH, Allen R, Baldessarini RJ. Spillover effects on treatment of adult depression in primary care after FDA advisory on risk of pediatric suicidality with SSRIs. Am J Psychiatry 2007; 164: 1198-205.
8. Medicines and Healthcare Products Regulatory Agency (MHRA). Committee on Safety of Medicines Assessment Report: Seroxat (Paroxetine)-Safety and Efficacy in the Paediatric Population. MHRA, 2003 (http://webarchive. nationalarchives.gov.uk/20141205150130/http://www.mhra.gov.uk/home/groups/es-policy/documents/websiteresources/con014159.pdf ).
9. Food and Drug Administration. Overview for December 13 Meeting of Psychopharmacologic Drugs Advisory Committee (PDAC). FDA, 2006 (http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4272b1-01-FDA.pdf).
10. Hammad TA, Laughren TP, Racoosin JA. Suicide rates in short-term randomized controlled trials of newer antidepressants. J Clin Psychopharmacol 2006; 26: 203-7.
11. Saperia J, Ashby D, Gunnell D. Suicidal behaviour and SSRIs: updated metaanalysis. BMJ 2006; 332: 1453.
12. Gunnell D, Saperia J, Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review. BMJ 2005; 330: 385.
13. Simon GE, Savarino J, Operskalski B, Wang PS. Suicide risk during antidepressant treatment. Am J Psychiatry 2006; 163: 41-7.
14. Martinez C, Rietbrock S, Wise L, Ashby D, Chick R, Moseley J, et al. Antidepressant treatment and the risk of fatal and non-fatal self harm in first episode depression: nested case-control study. BMJ 2005; 330: 389.
15. Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behaviors. JAMA 2004; 292: 338-43.
16. Schneeweiss S, Patrick AR, Solomon DH, Mehta J, Dormuth C, Miller M, et al. Variation in the risk of suicide attempts and completed suicides by antidepressant agent in adults: a propensity score-adjusted analysis of 9 years' data. Arch Gen Psychiatry 2010; 67: 497-506.
17. IMS Health. IMS LifeLinkTM Health Plan Claims Data User Guide & Data Dictionary. IMS Health, 2011.
18. World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. WHO, 1992.
19. Centers for Disease Control and Prevention. Injury Prevention & Control: Data & Statistics (WISQARSTM). Table 1. Recommended Framework of E-code Groupings for Presenting Injury Mortality and Morbidity Data (August 10, 2011). CDC, 2011 (http://www.cdc.gov/injury/wisqars/ecode-matrix.html).
20. Centers for Disease Control and Prevention. Tools for Classifying ICD Codes: External Cause-of-Injury (E-code) Matrices. Codes for the Matrix. Centers for Disease Control and Prevention, 2011. Available at: http://www.cdc.gov/nchs/injury/injury-tools.htm (accessed 20 Oct 2015).
21. Malone D, Billups S, Valuck R, Carter BL. Development of a chronic disease indicator score using a Veterans Affairs Medical Center medication database. J Clin Epidemiol 1999; 52: 551-7.
22. D'Hoore W, Bouckaert A, Tilquin C. Practical considerations on the use of the Charlson comorbidity index with administrative data bases. J Clin Epidemiol 1996; 49: 1429-33.
23. Cleophas TJ, Zwinderman AH. Propensity Score Matching. Statistics Applied to Clinical Studies. Springer Netherlands, 2012.
24. Whyte IM, Dawson AH, Buckley NA. Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants. QJM 2003; 96: 369-74.
25. Rubino A, Roskell N, Tennis P, Mines D, Weich S, Andrews E. Risk of suicide during treatment with venlafaxine, citalopram, fluoxetine, and dothiepin: retrospective cohort study. BMJ 2007; 334: 242.
26. Mines D, Hill D, Yu H, Novelli L. Prevalence of risk factors for suicide in patients prescribed venlafaxine, fluoxetine, and citalopram. Pharmacoepidemiol Drug Saf 2005; 14: 367-72.
27. Velentgas P, Dreyer NA, Nourjah P, Smith SR, Torchia MM. Developing a Protocol for Observational Comparative Effectiveness Research: A User's Guide. AHRQ Publication No. 12(13)-EHC099. Agency for Healthcare Research and Quality, 2013.
28. Valuck RJ, Libby AM, Sills MR, Giese AA, Allen RR. Antidepressant treatment and risk of suicide attempt by adolescents with major depressive disorder: a propensity-adjusted retrospective cohort study. CNS Drugs 2004; 18: 1119-32.